Fluidigm and Next Gen Diagnostics Enter into Agreement to Improve the Efficiency of Pathogen Sample Preparation for Microbial Whole Genome Sequencing

PRESS RELEASE
Written By Casey-Drew Williams

Fluidigm Corporation (Nasdaq:FLDM), an industry leader in microfluidics technology, and Next Gen Diagnostics (NGD), a Wellcome Sanger Institute-based leader in the automation of pathogen bioinformatics, today announce an exclusive agreement that enables NGD to utilize the Fluidigm® Juno™ system for pathogen whole genome sequencing (WGS) sample preparation. Under the terms of the agreement, Fluidigm will receive milestone payments starting in 2020 and additional revenue over five years.

Casey-Drew Williams
Previous

Next Gen Diagnostics Announces that MIT Associate Professor and Broad Institute Core Faculty member Paul Blainey has Joined its Scientific Advisory Board
Next

Next Gen Diagnostics Announces that Dr. Tony Cox, Director of Advanced Sequencing Pipeline Research at the Wellcome Sanger Institute, Has Joined its Scientific Advisory Board